XRAY
DENTSPLY SIRONA Inc.
Medical - Instruments & Supplies
Market Cap$2.20B
5Y Perf.-76.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XRAY vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
XRAY vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XRAY | DBVT |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $2.20B | $1712.35T |
| Revenue (TTM) | $3.68B | $0.00 |
| Net Income (TTM) | $-628M | $-168M |
| Gross Margin | 48.9% | — |
| Operating Margin | 4.1% | — |
| Forward P/E | 7.7x | — |
| Total Debt | $2.47B | $22M |
| Cash & Equiv. | $326M | $194M |
XRAY vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XRAY
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| DENTSPLY SIRONA Inc. (XRAY) | 100 | 23.6 | -76.4% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XRAY vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XRAY and DBVT are tied at the top with 3 categories each — the right choice depends on your priorities. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
XRAY
DENTSPLY SIRONA Inc.
The Income Pick
XRAY carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 23 yrs, beta 1.78, yield 5.9%
- Rev growth -3.0%, EPS growth 33.0%, 3Y rev CAGR -2.1%
- -74.5% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Defensive Pick
DBVT is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
- 0.3% margin vs XRAY's -17.1%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XRAY | -3.0% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs XRAY's -17.1% |
| Stability / Safety | DBVT | Beta 1.26 vs XRAY's 1.78, lower leverage |
| Dividends | XRAY | 5.9% yield; 23-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs XRAY's -16.4% |
| Efficiency (ROA) | XRAY | -11.2% ROA vs DBVT's -89.0% |
XRAY vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
Segment breakdown not available.
XRAY vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGXRAY
XRAYDENTSPLY SIRONA Inc.
2leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs XRAYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XRAY5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
XRAY1/1
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
XRAY and DBVT operate at a comparable scale, with $3.7B and $0 in trailing revenue.
| Metric | XRAYDENTSPLY SIRONA I… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $3.7B | $0 |
| EBITDAEarnings before interest/tax | $424M | -$112M |
| Net IncomeAfter-tax profit | -$628M | -$168M |
| Free Cash FlowCash after capex | $104M | -$151M |
| Gross MarginGross profit ÷ Revenue | +48.9% | — |
| Operating MarginEBIT ÷ Revenue | +4.1% | — |
| Net MarginNet income ÷ Revenue | -17.1% | — |
| FCF MarginFCF ÷ Revenue | +2.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +0.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -150.0% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — XRAY and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | XRAYDENTSPLY SIRONA I… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $2.2B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $4.3B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -3.65x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.68x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 7.18x | — |
| Price / SalesMarket cap ÷ Revenue | 0.60x | — |
| Price / BookPrice ÷ Book value/share | 1.63x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 21.11x | — |
Evenly matched — XRAY and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
XRAY leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
XRAY delivers a -41.2% return on equity — every $100 of shareholder capital generates $-41 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to XRAY's 1.84x. On the Piotroski fundamental quality scale (0–9), XRAY scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | XRAYDENTSPLY SIRONA I… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -41.2% | -130.2% |
| ROA (TTM)Return on assets | -11.2% | -89.0% |
| ROICReturn on invested capital | +5.1% | — |
| ROCEReturn on capital employed | +6.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 1.84x | 0.13x |
| Net DebtTotal debt minus cash | $2.1B | -$172M |
| Cash & Equiv.Liquid assets | $326M | $194M |
| Total DebtShort + long-term debt | $2.5B | $22M |
| Interest CoverageEBIT ÷ Interest expense | -5.12x | -189.82x |
XRAY leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $1,991 for XRAY. Over the past 12 months, DBVT leads with a +110.4% total return vs XRAY's -16.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs XRAY's -32.6% — a key indicator of consistent wealth creation.
| Metric | XRAYDENTSPLY SIRONA I… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -2.8% | +4.9% |
| 1-Year ReturnPast 12 months | -16.4% | +110.4% |
| 3-Year ReturnCumulative with dividends | -69.4% | +19.7% |
| 5-Year ReturnCumulative with dividends | -80.1% | -69.1% |
| 10-Year ReturnCumulative with dividends | -74.5% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -32.6% | +6.2% |
DBVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than XRAY's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs XRAY's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XRAYDENTSPLY SIRONA I… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 1.26x |
| 52-Week HighHighest price in past year | $17.18 | $26.18 |
| 52-Week LowLowest price in past year | $9.85 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 39.2 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
XRAY leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates XRAY as "Hold" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 22.3% for XRAY (target: $13). XRAY is the only dividend payer here at 5.86% yield — a key consideration for income-focused portfolios.
| Metric | XRAYDENTSPLY SIRONA I… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $13.40 | $46.33 |
| # AnalystsCovering analysts | 31 | 15 |
| Dividend YieldAnnual dividend ÷ price | +5.9% | — |
| Dividend StreakConsecutive years of raises | 23 | 0 |
| Dividend / ShareAnnual DPS | $0.64 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
XRAY leads this category, winning 1 of 1 comparable metric.
Key Takeaway
DBVT leads in 3 of 6 categories (Income & Cash Flow, Total Returns). XRAY leads in 2 (Profitability & Efficiency, Analyst Outlook). 1 tied.
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
XRAY vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is XRAY or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XRAY or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -80. 1% for DENTSPLY SIRONA Inc. (XRAY). Over 10 years, the gap is even starker: XRAY returned -74. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XRAY or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus DENTSPLY SIRONA Inc. 's 1. 78β — meaning XRAY is approximately 42% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — XRAY or DBVT?
On earnings-per-share growth, the picture is similar: DENTSPLY SIRONA Inc.
grew EPS 33. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — XRAY or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -16. 3% for DENTSPLY SIRONA Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XRAY leads at 6. 8% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — XRAY leads at 50. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is XRAY or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
07Which pays a better dividend — XRAY or DBVT?
In this comparison, XRAY (5.
9% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.
08Is XRAY or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DENTSPLY SIRONA Inc.
(XRAY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (5. 9% yield). Both have compounded well over 10 years (XRAY: -74. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between XRAY and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XRAY is a small-cap income-oriented stock; DBVT is a mega-cap quality compounder stock. XRAY pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.